<html><head></head><body><h1>Carmustine</h1><p class="drug-subtitle"><b>Class:</b> Antineoplastic Agents<br/>
- Alkylating Agents<br/>
<b>VA Class:</b> AN100<br/>
<b>CAS Number:</b> 154-93-8<br/>
<b>Brands:</b> BiCNU, Gliadel Wafer</p><ul class="ddc-anchor-links"><li>Uses</li>
<li>Dosage</li>
<li>Cautions</li>
<li>Interactions</li>
<li>Pharmacokinetics</li>
<li>Patient advice</li>
<li>Preparations</li></ul><h3>Warning</h3><ul>Warning Information for IV Carmustine
<li>
<p>Use under supervision of a qualified clinician experienced in therapy with antineoplastic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of bone marrow suppression (e.g., thrombocytopenia, leukopenia), resulting in bleeding and infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Bone marrow toxicity is delayed and cumulative.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor CBCs weekly during and for at least 6 weeks following each dose; do not administer more frequently than every 6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Adjust subsequent dosages based on nadir blood counts from previous dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration.)</p>
</li>
<li>
<p>Risk of dose-related pulmonary toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Cumulative doses &gt;1400 mg/m<sup>2</sup> associated with substantially greater risk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Delayed pulmonary toxicity can occur years after treatment and result in death, particularly in patients treated during childhood.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Use under supervision of a qualified clinician experienced in therapy with antineoplastic agents.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of bone marrow suppression (e.g., thrombocytopenia, leukopenia), resulting in bleeding and infection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Bone marrow toxicity is delayed and cumulative.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor CBCs weekly during and for at least 6 weeks following each dose; do not administer more frequently than every 6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Adjust subsequent dosages based on nadir blood counts from previous dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Dosage Modification for Toxicity under Dosage and Administration.)</p><p>Risk of dose-related pulmonary toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Cumulative doses &gt;1400 mg/m<sup>2</sup> associated with substantially greater risk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Delayed pulmonary toxicity can occur years after treatment and result in death, particularly in patients treated during childhood.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Introduction</h2><p>Antineoplastic agent; a nitrosourea-derivative alkylating agent.</p><h2 class="ddc-anchor-offset" id="uses">Uses for Carmustine</h2><h3>Brain Tumors: Conventional Chemotherapy</h3><p>Adjunct to radiation therapy following surgery for palliative treatment of malignant glioma (i.e., astrocytoma, ependymoma, medulloblastoma, brainstem glioma) and metastatic brain tumors.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;125&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Among several preferred chemotherapeutic regimens for anaplastic astrocytoma and glioblastoma multiforme.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;125&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Has not been shown to increase survival time, but a trend toward a higher long-term survival rate (e.g., at 18 months) has been observed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;126&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;127&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjuvant or salvage therapy for oligodendroglioma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;127&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;128&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Surgery with or without radiation therapy currently considered standard treatment for ependymoma and medulloblastoma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Radiation therapy considered standard treatment for brainstem glioma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;c&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Brain Tumors: Intracranial Wafer Implant</h3><p>Adjunct to surgery and radiation for treatment of newly diagnosed high-grade malignant glioma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Among several preferred chemotherapeutic regimens for anaplastic astrocytoma and glioblastoma multiforme.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjunct to surgery for treatment of recurrent glioblastoma multiforme.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;135&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;137&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Multiple Myeloma</h3><p>Carmustine-containing regimens considered alternative therapy for palliative treatment of multiple myeloma.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;138&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Hodgkin’s Disease</h3><p>Used in combination with other agents as secondary therapy for treatment of refractory or relapsed Hodgkin’s disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Combination regimens containing other agents currently are preferred as initial or alternative therapy for this cancer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;141&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Non-Hodgkin’s Lymphoma</h3><p>Used in combination with other agents as secondary therapy for treatment of refractory or relapsed non-Hodgkin’s lymphomas.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Combination regimens containing other agents currently are preferred as initial or alternative therapy for these cancers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;144&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Melanoma</h3><p>Has been used alone&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or in combination therapy&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;114&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;116&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;119&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; for palliative treatment of metastatic melanoma†; however, low response rate and substantial toxicity limit this use of carmustine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;117&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;122&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Cutaneous T-cell Lymphoma</h3><p>Used topically† for palliative treatment of cutaneous T-cell lymphoma (mycosis fungoides)†.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;123&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="dosage">Carmustine Dosage and Administration</h2><h3>General</h3><ul>
<li>
<p>Consult specialized references for procedures for proper handling and disposal of antineoplastics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Consult specialized references for procedures for proper handling and disposal of antineoplastics.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Administration</h3><p>Administer by IV infusion&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or intracranially as wafer implants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been administered by intra-arterial† (into the carotid artery) route; however, such administration has been associated with ocular toxicity&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (blindness), fatal encephalopathy, and inferior survival.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;132&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Has been administered topically† as a 0.05–0.4% hydroalcoholic solution or as an ointment, but dosage forms for such use are not commercially available in US; consult specialized references.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;100&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;120&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>For solution and drug compatibility information, see Compatibility under Stability.</p><p>Vials are for single use only.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use glass containers for administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Handle cautiously (e.g., use gloves); avoid exposure during handling of powder and preparation of IV solution.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>If skin or mucosal contact occurs, immediately wash affected area(s) thoroughly with soap and water.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Add 3 mL of diluent provided by manufacturer (sterile dehydrated [absolute] alcohol) to vial containing 100 mg of carmustine; then add 27 mL of sterile water for injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Resulting solution contains 3.3 mg/mL carmustine in 10% ethanol.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Dilute with 5% dextrose injection.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Administer by IV infusion over 1–2 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; More rapid administration associated with adverse effects.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Local Effects under Cautions.)</p><p>Handle with care (cytotoxic material);&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; use double surgical gloves and discard outer gloves into biohazard waste container after use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Wafers broken in half may be used; discard in biohazard container if broken in &gt;2 pieces.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Deliver aluminum foil laminate pouches containing wafer to operating room; do not open until ready to implant.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Outside surface of outer foil pouch is <i>not</i> sterile.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use surgical instrument dedicated to handling carmustine wafers to implant the wafers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Implant intracranially in the resection cavity following surgical resection of brain tumor.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Place oxidized regenerated cellulose (Surgicel<sup></sup>) over wafers to secure them against surface of resection cavity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Following placement of wafers, irrigate resection cavity and close dura in a watertight fashion to minimize risk of CSF leak.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Dosage</h3><p>As monotherapy in previously untreated patients, 150–200 mg/m<sup>2</sup> administered as a single dose or in divided doses (e.g., 75–100 mg/m<sup>2</sup> on 2 successive days) at intervals of at least 6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Up to 8 wafers (total carmustine dose: 61.6 mg) intracranially to cover as much of the resection cavity as possible (slight overlapping permissible).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If size and shape of cavity will not allow placement of 8 wafers, use maximum possible number.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not place &gt;8 wafers intracranially per surgical procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In clinical trials, chemotherapy was withheld for at least 4 weeks (6 weeks for nitrosoureas) prior to and 2 weeks after surgery;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; external beam radiation therapy was administered no sooner than 3 weeks after surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;151&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>As monotherapy in previously untreated patients, 150–200 mg/m<sup>2</sup> administered as a single dose or in divided doses (e.g., 75–100 mg/m<sup>2</sup> on 2 successive days) at intervals of at least 6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>As monotherapy in previously untreated patients, 150–200 mg/m<sup>2</sup> administered as a single dose or in divided doses (e.g., 75–100 mg/m<sup>2</sup> on 2 successive days) at intervals of at least 6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>As monotherapy in previously untreated patients, 150–200 mg/m<sup>2</sup> administered as a single dose or in divided doses (e.g., 75–100 mg/m<sup>2</sup> on 2 successive days) at intervals of at least 6 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Reduce dosage if used in combination with other myelosuppressive drugs or in patients with compromised bone marrow function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Adjust subsequent dosages based on nadir blood counts from preceding dose (see Dosage Modification for Toxicity under Dosage and Administration).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Usual topical dosage is 10 mg once daily for 7–14 weeks (maximum: 17 weeks).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If response is inadequate, after a rest interval of 6 weeks, administer second course of topical therapy with 20 mg once daily for 4–8 weeks, as tolerated.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Topical dosage form not commercially available in US; consult specialized references for specific information on topical use.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;149&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;150&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Do not administer repeat courses until leukocyte count &gt;4000/mm<sup>3</sup>, platelet count &gt;100,000/mm<sup>3</sup>, and an adequate number of neutrophils is present on peripheral blood smear.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Bone marrow toxicity is cumulative; adjust subsequent dosages based on nadir blood counts from previous dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Leukocytes (cells/mm<sup>3</sup>)</p><p>Platelets (cells/mm<sup>3</sup>)</p><p>Percentage of Prior Dose to be Given</p><p>&gt;4000</p><p>&gt;100,000</p><p>100%</p><p>3000–3999</p><p>75,000–99,999</p><p>100%</p><p>2000–2999</p><p>25,000–74,999</p><p>70%</p><p>&lt;2000</p><p>&lt;25,000</p><p>50%</p><p>Alternatively, to avoid potential overdosage associated with manufacturer’s suggested modifications, some clinicians recommend reducing subsequent dosage by 25% when platelet nadirs are 50,000–74,999/mm<sup>3</sup>; by 50% for nadirs of 25,000–49,999/mm<sup>3</sup>; and by 75% for nadirs &lt;25,000/mm<sup>3</sup>.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Prescribing Limits</h3><p>Maximum 8 wafers per surgical procedure.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Special Populations</h3><p>Select IV dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;148&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Geriatric Use under Cautions.)</p><h2 class="ddc-anchor-offset" id="cautions">Cautions for Carmustine</h2><h3>Contraindications</h3><ul>
<li>
<p>Known hypersensitivity to carmustine or any ingredient in the formulations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Known hypersensitivity to carmustine or any ingredient in the formulations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Warnings/Precautions</h3><p>Risk of myelosuppression (e.g., thrombocytopenia, leukopenia) following IV carmustine; effects are delayed and cumulative.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Boxed Warning.) Thrombocytopenia generally more severe than leukopenia but both considered dose-limiting toxicities.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Anemia reported less frequently and is less severe.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IV administration, thrombocytopenia and leukopenia occur at approximately 4 and 5–6 weeks, respectively, and persist for 1–2 weeks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Repeated dosing associated with more severe and more prolonged myelosuppression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Use with caution in patients with depressed platelet, leukocyte, or erythrocyte counts.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With IV carmustine, risk of dose-related, sometimes fatal, pulmonary toxicity (characterized by pulmonary infiltrates and/or fibrosis).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Boxed Warning.) Risk factors include prolonged therapy (with cumulative doses &gt;1400 mg/m<sup>2</sup>) and history of lung disease.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of delayed-onset pulmonary fibrosis (occurred up to 17 years after treatment during childhood and early adolescence); possible reduction of pulmonary function or death.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Pediatric Use under Cautions.)</p><p>Perform pulmonary function tests prior to initiation of and frequently during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Patients with baseline forced vital capacity (FVC) or pulmonary diffusion capacity for carbon monoxide (DL<sub>CO</sub>) &lt;70% of predicted value are particularly at risk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of secondary malignancies following long-term use of nitrosoureas.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Intracerebral mass effect unresponsive to corticosteroids reported, including one case leading to brain herniation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Brain edema with mass effect (due to tumor recurrence, intracranial infection, or necrosis) may necessitate reoperation and, in some cases, removal of wafer or wafer remnants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of seizures; median time to onset is 3.5 days.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Formation of tumor bed cyst unresponsive to high-dose corticosteroids reported; required reoperation for drainage following implantation of carmustine wafers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;136&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor patients closely for potential complications of craniotomy (e.g., seizures, intracranial infections, abnormal wound healing, brain edema).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Possible fetal harm; teratogenicity and embryotoxicity demonstrated in animals.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Avoid pregnancy during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If used during pregnancy or if patient becomes pregnant, apprise of potential fetal hazard.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Rapid IV infusion may result in intensive flushing of the skin and suffusion of the conjunctiva; these effects occur within 2 hours and persist for 4 hours after IV administration.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also associated with intense pain and burning at injection site; thrombosis is rare.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With intracranial wafer implant, wound dehiscence; delayed wound healing; subdural, subgaleal, or wound effusions; and CSF leak reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With intracranial wafer implant, abscess, meningitis, and pneumonia reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Sepsis reported but causal relationship not established.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With IV carmustine, dose-related nausea and vomiting reported within 2 hours and persisting for 4–6 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Premedication with antiemetics may diminish or prevent.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>After IV therapy, reversible increases in serum transaminase, alkaline phosphatase, and bilirubin concentrations reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Possible hepatic dysfunction.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor hepatic function periodically.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>After prolonged IV therapy (with large cumulative doses), progressive azotemia, decrease in kidney size, and renal failure reported.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Kidney damage reported occasionally in patients receiving lower total doses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Monitor renal function periodically.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Evaluate carmustine benefits against possible risks.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Most adverse effects are reversible if detected early with appropriate management (e.g., dosage reduction, discontinuance, appropriate corrective measures).&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Reinstitute with caution, considering risks and benefits.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of transient hyperpigmentation of skin with accidental dermal exposure; immediately wash exposed skin or mucosa.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of wafer migration from surgical resection cavity into ventricular system, leading to obstructive hydrocephalus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If communication between surgical resection cavity and ventricular system is larger than diameter of wafers, close such communication prior to implantation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Enhancement in brain tissue surrounding resection cavity (demonstrated by CT scan or MRI) following intracranial implantation may represent edema and inflammation caused by wafer or tumor progression.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>With IV therapy, monitor CBCs weekly during and for at least 6 weeks following each dose.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Also monitor pulmonary, hepatic, and renal function tests periodically during treatment.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Category D.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Fetal/Neonatal Morbidity and Mortality under Cautions.)</p><p>Not known whether carmustine is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discontinue nursing because of potential risk to nursing infants.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Not known whether constituents of polifeprosan 20 copolymer (i.e., carboxyphenoxypropane, sebacic acid) intracranial wafer are distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of IV carmustine not established in children.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Fatal pulmonary fibrosis reported with delayed onset up to 17 years following IV treatment of brain tumors during childhood or adolescence.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Extremely high risk of fatal pulmonary toxicity, particularly in children &lt;5 years of age at initial treatment; carefully weigh benefits and risks of therapy in pediatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Safety and efficacy of intracranial wafer implant not established in pediatric patients.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and potential for concomitant disease and drug therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;148&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Systemic carmustine substantially eliminated by kidneys; monitor renal function periodically since geriatric patients are more likely to have decreased renal function.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;148&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Common Adverse Effects</h3><p>For IV carmustine, pulmonary infiltrates and/or fibrosis, thrombocytopenia, leukopenia, anemia, nausea, vomiting, hepatic and renal toxicity.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; (See Warnings/Precautions under Cautions.)</p><p>For intracranial wafer, hemiplegia, seizures, confusion, brain edema, headache, asthenia, nausea, vomiting, constipation, infection, fever, aphasia, abnormal healing, depression, pain, rash, somnolence, speech disorder, deep thrombophlebitis, alopecia.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="interactions">Interactions for Carmustine</h2><h3>Intracranial Wafer</h3><p>No formal drug interaction studies to date.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In clinical trials, chemotherapy was withheld for at least 4 weeks (6 weeks for nitrosoureas) prior to and 2 weeks after surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Implantation in conjunction with radiotherapy does not appear to have any short-term or chronic toxicities;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; in clinical trials, external beam radiation therapy was administered &gt;3 weeks after surgery.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Specific Drugs</h3><p>Drug</p><p>Interaction</p><p>Comments</p><p>Cimetidine</p><p>Potentiation of neutropenic and thrombocytopenic effect of carmustine&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Mitomycin</p><p>Possible changes in tear films, with subsequent damage of corneal and conjunctival epithelium&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;146&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Phenytoin</p><p>Possible decreased serum phenytoin concentrations&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;147&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Monitor serum phenytoin concentrations carefully and adjust dosage accordingly&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;147&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="pharmacokinetics">Carmustine Pharmacokinetics</h2><h3>Absorption</h3><p>Intracranial wafer: Plasma concentrations following intracranial implantation not determined in humans; not detectable in plasma of rabbits undergoing surgical implantation of 3.85% carmustine wafers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Absorption of biodegradable copolymer from wafers has not been evaluated in humans.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Distribution</h3><p>Readily crosses the blood-brain barrier (due to high lipid solubility); concentrations of radioactivity in CSF are ≥50% of concurrent plasma concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Not known whether carmustine is distributed into milk.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Intracranial wafer: Concentration achieved in brain tissue not determined.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Not detectable in CSF of rabbits undergoing surgical implantation of 3.85% carmustine wafers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Distribution of biodegradable copolymer from wafers has not been evaluated in humans.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Elimination</h3><p>Rapidly metabolized and cleared from plasma following IV administration; no intact drug detectable after 15 minutes.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Antineoplastic and toxic effects believed to be caused by active metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Intracranial wafer: Carmustine is released and diffuses into brain tissue after hydrolysis of anhydride bonds in implant copolymer.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Metabolism of copolymer not evaluated in humans; 2 monomers (carboxyphenoxypropane and sebacic acid) are released.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Excreted principally in urine as metabolites.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Following IV administration, about 30 or 60–70% of radioactivity excreted within 24&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;38&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; or 96 hours, respectively.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; About 6–10% of radioactivity excreted as respiratory carbon dioxide.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Intracranial wafer: Biodegradable in human brain.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; In animal studies, &gt;70% of polifeprosan 20 copolymer degrades into monomers within 3 weeks of implantation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Carboxyphenoxypropane is eliminated renally; sebacic acid is metabolized in liver and expired as carbon dioxide.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>22 minutes following IV infusion.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>In humans, wafer remnants have been observed on brain imaging scans or located during subsequent surgical procedures up to 8 months following intracranial implantation.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Wafer remnants retrieved from 2 patients approximately 2–3 months after implantation consisted mostly of water and monomers with minimal carmustine.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2>Stability</h2><h3>Storage</h3><p>2–8°C; discard after 3 years.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Lyophilized powder decomposes to an oily liquid at temperatures ≥30.5°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Upon receipt, inspect vials that may <i>not</i> have been refrigerated adequately by holding them up to bright light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard if an oily film is present.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; If dry flakes or a dry, congealed mass is present, vial is suitable for use; refrigerate immediately.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Store reconstituted solution in glass container at 25°C; protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard after 8 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Store diluted solution in glass container at 25°C; protect from light.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Discard after 8 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>≤−20°C.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Do not open aluminum foil laminate pouches containing wafer until immediately prior to implantation in the operating room.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>May keep unopened foil pouches at ambient room temperature for up to 6 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h3>Compatibility</h3><p>For information on systemic interactions resulting from concomitant use, see Interactions.</p><p>Compatible for 8 hours at 25°C;&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;101&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; use within 8 hours.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Compatible</p><p>Sodium chloride 0.9%</p><p>Variable</p><p>Dextrose 5% in water</p><p>Incompatible</p><p>Sodium bicarbonate</p><p>Compatible</p><p>Amifostine</p><p>Aztreonam</p><p>Cefepime HCl</p><p>Etoposide phosphate</p><p>Filgrastim</p><p>Fludarabine phosphate</p><p>Gemcitabine HCl</p><p>Granisetron HCl</p><p>Melphalan HCl</p><p>Ondansetron HCl</p><p>Piperacillin sodium–tazobactam sodium</p><p>Sargramostim</p><p>Teniposide</p><p>Thiotepa</p><p>Vinorelbine tartrate</p><p>Incompatible</p><p>Allopurinol sodium</p><h2>Actions</h2><ul>
<li>
<p>Alkylates DNA and RNA.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Overall result is thought to be the inhibition of both DNA and RNA synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Cytotoxic effect of wafer depends on release of sufficient amounts of carmustine in the tumor cavity to achieve tumoricidal concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
</ul><p>Alkylates DNA and RNA.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; May inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Overall result is thought to be the inhibition of both DNA and RNA synthesis.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Cytotoxic effect of wafer depends on release of sufficient amounts of carmustine in the tumor cavity to achieve tumoricidal concentrations.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><h2 class="ddc-anchor-offset" id="patient-advice">Advice to Patients</h2><ul>
<li>
<p>Risk of myelosuppression or pulmonary toxicity with conventional chemotherapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of adherence to laboratory appointment schedules.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Notify clinician if fever, sore throat, or unusual bleeding or bruising occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Risk of post-implantation complications with wafers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of women informing their clinician if they are or plan to become pregnant or to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women avoiding pregnancy during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise pregnant women of risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p>
</li>
<li>
<p>Importance of informing patients of other important precautionary information. (See Cautions.)</p>
</li>
</ul><p>Risk of myelosuppression or pulmonary toxicity with conventional chemotherapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of adherence to laboratory appointment schedules.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Notify clinician if fever, sore throat, or unusual bleeding or bruising occurs.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;d&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Risk of post-implantation complications with wafers.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of women informing their clinician if they are or plan to become pregnant or to breast-feed.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Importance of women avoiding pregnancy during therapy.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; Advise pregnant women of risk to the fetus.&lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;105&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt; &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;sup&gt;124&lt;/sup&gt;&lt;/body&gt;&lt;/html&gt;</p><p>Importance of informing patients of other important precautionary information. (See Cautions.)</p><h2 class="ddc-anchor-offset" id="preparations">Preparations</h2><p><i>Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.</i></p><p><i>Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.</i></p><p>Routes</p><p>Dosage Forms</p><p>Strengths</p><p>Brand Names</p><p>Manufacturer</p><p>Local</p><p>For injection, for IV infusion</p><p>100 mg</p><p>BiCNU<sup></sup> (with 3 mL dehydrated [absolute] alcohol diluent)</p><p>Bristol-Myers Squibb</p><p>Local</p><p>Implants</p><p>7.7 mg (of carmustine per wafer)</p><p>Gliadel<sup></sup> <b>Wafer</b> (with polifeprosan 20)</p><p>Guilford</p><p>AHFS<sup></sup> DI Essentials™. © Copyright 2021, Selected Revisions August 1, 2007. American Society of Health-System Pharmacists, Inc., 4500 East-West Highway, Suite 900, Bethesda, Maryland 20814.</p><p>† Use is not currently included in the labeling approved by the US Food and Drug Administration.</p><h2>References</h2><p>Only references cited for selected revisions after 1984 are available electronically.</p><p>38. Kleinman LM et al. Investigational drug information. <i>Drug Intell Clin Pharm</i>. 1976; 10:48-9.</p><p>100. Zackheim HS, Epstein EH Jr, McNutt NS et al. Topical carmustine (BCNU) for mycosis fungoides and related disorders. <i>J Am Acad Dermatol</i>. 1983; 9:363-74. http://www.ncbi.nlm.nih.gov/pubmed/6630597?dopt=AbstractPlus</p><p>101. Lauper RD (Bristol-Myers Oncology, Syracuse, NY): Personal communication; 1985 Nov.</p><p>102. Benvenuto JA, Anderson RW, Kerkov K et al. Stability and compatibility of antitumor agents in glass and plastic containers. <i>Am J Hosp Pharm</i>. 1981; 38: 1914-8.</p><p>103. Laskar PA, Ayres JW. Degradation of carmustine in aqueous media. <i>J Pharm Sci</i>. 1977; 66:1073-6. http://www.ncbi.nlm.nih.gov/pubmed/19612?dopt=AbstractPlus</p><p>104. Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. <i>Am J Hosp Pharm</i>. 1980; 37:677-8. http://www.ncbi.nlm.nih.gov/pubmed/7386477?dopt=AbstractPlus</p><p>105. Bristol-Myers Squibb. BiCNU<sup></sup> (carmustine for injection) prescribing information. Princeton, NJ; 2003 Oct.</p><p>106. Patten GA, Billi JE, Rotman HH. Rapidly progressive, fatal pulmonary fibrosis induced by carmustine. <i>JAMA</i>. 1980; 244:687-8. http://www.ncbi.nlm.nih.gov/pubmed/7392168?dopt=AbstractPlus</p><p>107. Johnson R, Douglas J, Corey L et al. Carmustine and myelodysplasia. <i>Ann Intern Med</i>. 1985; 103(6 Part 1):964-5.</p><p>108. Greene MH, Boice JD Jr, Strike TA. Carmustine as a cause of acute nonlymphocytic leukemia. <i>N Engl J Med</i>. 1985; 313:579. http://www.ncbi.nlm.nih.gov/pubmed/3894973?dopt=AbstractPlus</p><p>109. Durant JR, Norgard MJ, Murad TM et al. Pulmonary toxicity associated with bischloroethylnitrosourea (BCNU). <i>Ann Intern Med</i>. 1979; 90:191-4. http://www.ncbi.nlm.nih.gov/pubmed/443651?dopt=AbstractPlus</p><p>110. Weiss RB, Muggia FM. Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU). <i>Ann Intern Med</i>. 1979; 91:131-2. http://www.ncbi.nlm.nih.gov/pubmed/464441?dopt=AbstractPlus</p><p>111. Sweet DL. Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU). <i>Ann Intern Med</i>. 1979; 91:132. http://www.ncbi.nlm.nih.gov/pubmed/464443?dopt=AbstractPlus</p><p>112. Durant JR. Pulmonary effects of carmustine (bischloroethylnitrosourea, BCNU). <i>Ann Intern Med</i>. 1979; 91:132-3.</p><p>113. Food and Drug Administration. Prescription drug advertising; content and format for labeling of human prescription drugs. <i>Fed Regist</i>. 1979; 44:37434-67.</p><p>114. Melanoma. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Jun.</p><p>115. Duran Garcia E, Santolaya R, Requena T. Treatment of malignant melanoma. <i>Ann Pharmacother</i>. 1999; 33:730-8. http://www.ncbi.nlm.nih.gov/pubmed/10410188?dopt=AbstractPlus</p><p>116. Cohen GL, Falkson CI. Current treatment options for malignant melanoma. <i>Drugs</i>. 1998; 55:791-9. http://www.ncbi.nlm.nih.gov/pubmed/9617594?dopt=AbstractPlus</p><p>117. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b. <i>J Clin Oncol</i>. 1999; 17:968-75. http://www.ncbi.nlm.nih.gov/pubmed/10071291?dopt=AbstractPlus</p><p>118. Falkson CI, Ibrahim J, Kirkwood JM et al. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. <i>J Clin Oncol</i>. 1998; 16:1743-51. http://www.ncbi.nlm.nih.gov/pubmed/9586887?dopt=AbstractPlus</p><p>119. Margolin KA, Liu PY, Flaherty LE et al. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study. <i>J Clin Oncol</i>. 1998; 16:664-9. http://www.ncbi.nlm.nih.gov/pubmed/9469356?dopt=AbstractPlus</p><p>120. Anon. Drugs of choice for cancer. <i>Treat Guidel Med Lett</i>. 2003; 1:41-52. http://www.ncbi.nlm.nih.gov/pubmed/15529105?dopt=AbstractPlus</p><p>121. Chapman PB, Einhorn LH, Meyers ML et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. <i>J Clin Oncol</i>. 1999; 17:2745-51. http://www.ncbi.nlm.nih.gov/pubmed/10561349?dopt=AbstractPlus</p><p>122. Reviewers’ comments (personal observations) on melanoma.</p><p>123. Mycosis fungoides and the Sezary syndrome. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Sep.</p><p>124. Guilford Pharmaceuticals Inc. Gliadel<sup></sup> wafer (polifeprosan 20 with carmustine implant) prescribing information. Baltimore, MD; 2003 Feb.</p><p>125. DeAngelis LM. Brain tumors. <i>N Engl J Med</i>. 2001; 344:114-23. http://www.ncbi.nlm.nih.gov/pubmed/11150363?dopt=AbstractPlus</p><p>126. Walker MD, Alexander E Jr, Hunt WE et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. <i>J Neurosurg</i>. 1978; 49:333-43. http://www.ncbi.nlm.nih.gov/pubmed/355604?dopt=AbstractPlus</p><p>127. Walker MD, Green SB, Byar DP et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. <i>N Engl J Med</i>. 1980; 303:1323-9. http://www.ncbi.nlm.nih.gov/pubmed/7001230?dopt=AbstractPlus</p><p>128. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. <i>Ann Neurol</i>. 1988; 23:360-4. http://www.ncbi.nlm.nih.gov/pubmed/3382171?dopt=AbstractPlus</p><p>129. Galanis E, Buckner J. Chemotherapy for high-grade gliomas. <i>Br J Cancer</i>. 2000; 82:1371-80. http://www.ncbi.nlm.nih.gov/pubmed/10780513?dopt=AbstractPlus http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=pmcentrez&amp;artid=2363368&amp;blobtype=pdf</p><p>130. Fine HA, Dear KB, Loeffler JS et al. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. <i>Cancer</i>. 1993; 71:2585-97. http://www.ncbi.nlm.nih.gov/pubmed/8453582?dopt=AbstractPlus</p><p>131. Medical Research Council. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. <i>J Clin Oncol</i>. 2001; 19:509-18. http://www.ncbi.nlm.nih.gov/pubmed/11208845?dopt=AbstractPlus</p><p>132. Shapiro WR. Chemotherapy of malignant gliomas: studies of the BTCG. <i>Rev Neurol (Paris)</i>. 1992; 148:428-34. http://www.ncbi.nlm.nih.gov/pubmed/1448662?dopt=AbstractPlus</p><p>133. Brem H, Piantadosi S, Burger PC et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. <i>Lancet</i>. 1995; 345:1008-12. http://www.ncbi.nlm.nih.gov/pubmed/7723496?dopt=AbstractPlus</p><p>134. Valtonen S, Timonen U, Toivanen P et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. <i>Neurosurgery</i>. 1997; 41:44-8; discussion 48-9. http://www.ncbi.nlm.nih.gov/pubmed/9218294?dopt=AbstractPlus</p><p>135. Adult brain tumors. From PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2005 Mar 24.</p><p>136. Engelhard HH. Tumor bed cyst formation after BCNU wafer implantation: report of two cases. <i>Surg Neurol</i>. 2000; 53:220-4. http://www.ncbi.nlm.nih.gov/pubmed/10773252?dopt=AbstractPlus</p><p>137. Anon. Gliadel wafers for treatment of brain tumors. <i>Med Lett Drugs Ther</i>. 1998; 40:92. http://www.ncbi.nlm.nih.gov/pubmed/9760950?dopt=AbstractPlus</p><p>138. Multiple myeloma and other plasma cell neoplasms. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Oct.</p><p>139. Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. <i>J Clin Oncol</i>. 1998; 16:3832-42. http://www.ncbi.nlm.nih.gov/pubmed/9850028?dopt=AbstractPlus</p><p>140. Mineur P, Menard JF, Le Loet X et al. VAD or VMBCP in multiple myeloma refractory to or relapsing after cyclophosphamide-prednisone therapy (protocol MY 85). <i>Br J Haematol.</i> 1998;103:512-7.</p><p>141. Adult Hodgkin’s disease. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Sep.</p><p>142. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin’s disease. A single-center eight-year study of 155 patients. <i>Blood</i>. 1993; 81:1137-45. http://www.ncbi.nlm.nih.gov/pubmed/8443375?dopt=AbstractPlus</p><p>143. Nademanee A, O’apos;Donnell MR, Snyder DS et al. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. <i>Blood</i>. 1995; 85:1381-90. http://www.ncbi.nlm.nih.gov/pubmed/7858268?dopt=AbstractPlus</p><p>144. Adult non-Hodgkin’s lymphoma. From: CancerNet/PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2001 Oct.</p><p>145. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin’s lymphoma. <i>J Clin Oncol</i>. 1995; 13:588-95. http://www.ncbi.nlm.nih.gov/pubmed/7884420?dopt=AbstractPlus</p><p>146. Cruciani F, Tamanti N, Abdolrahimzadeh S et al. Ocular toxicity of systemic chemotherapy with megadoses of carmustine and mitomycin. <i>Ann Ophthalmol</i>. 1994; 26:97-100. http://www.ncbi.nlm.nih.gov/pubmed/7944163?dopt=AbstractPlus</p><p>147. Grossman SA, Sheidler VR, Gilbert MR. Decreased phenytoin levels in patients receiving chemotherapy. <i>Am J Med</i>. 1989; 87:505-10. http://www.ncbi.nlm.nih.gov/pubmed/2683764?dopt=AbstractPlus</p><p>148. Food and Drug Administration. MedWatch—Safety-related drug labeling changes: BiCNU (carmustine) [February 2003]. From FDA web site http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm.</p><p>149. Zackheim HS, Epstein EH Jr, Crain WR. Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. <i>J Am Acad Dermatol</i>. 1990; 22:802-10. http://www.ncbi.nlm.nih.gov/pubmed/2347966?dopt=AbstractPlus</p><p>150. Zackheim HS. Topical carmustine (BCNU) in the treatment of mycosis fungoides. <i>Dermatol Ther</i>. 2003; 16:299-302. http://www.ncbi.nlm.nih.gov/pubmed/14686972?dopt=AbstractPlus</p><p>151. Guilford Pharmaceuticals Inc. Gliadel<sup></sup> wafer (polifeprosan 20 with carmustine implant) prescribing information. Baltimore, MD; 2000 Aug.</p><p>c. Adult brain tumors. From: PDQ. Physician data query (database). Bethesda, MD: National Cancer Institute; 2006 Apr 6.</p><p>d. AHFS drug information 2003. McEvoy GK, ed. Carmustine. Bethesda, MD: American Society of Health-System Pharmacists; 2003:919-23.</p><p>HID. Trissel LA. Handbook on injectable drugs. 14th ed. Bethesda, MD: American Society of Health-System Pharmacists; 2007:263-6.</p><h2>More about carmustine</h2><ul class="more-resources-list more-resources-list-general">
<li>Side Effects</li>
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>Drug class: alkylating agents</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Carmustine Implantation &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
<li>Carmustine Intravenous &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(Advanced Reading)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li>Carmustine Injection &lt;html&gt;&lt;head&gt;&lt;/head&gt;&lt;body&gt;&lt;span&gt;(FDA)&lt;/span&gt;&lt;/body&gt;&lt;/html&gt;</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Brain Tumor</li>
<li>Glioblastoma Multiforme</li>
<li>Hodgkin's Lymphoma</li>
<li>Malignant Glioma</li>
<li>Multiple Myeloma</li>
<li>Non-Hodgkin's Lymphoma</li>
</ul><p class="ddc-disclaimer-link">Medical Disclaimer</p></body></html>